A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

Scientists have developed a novel approach of genome editing to repair muscle stem (satellite) cells, offering new hope for ...

Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex ...

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Scientists introduced CRISPR to the world as a gene-editing tool in summer 2012, when landmark papers from two independent groups demonstrated how the system could be wielded to make cuts in DNA. Now, ...

These “zombie” cells are damaged yet refuse to die. Instead, they linger in the body, infect healthy cells, and can contribute to age-related decline. In this webinar, Janaina Sena and Debra Silver ...

Crisp Therapeutics received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy in the world. Crispr shares were up close to 5% on the news. Don’t miss this list of 3 high-yield ...